Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Early and accurate diagnosis of primary vitreoretinal lymphoma is crucial to prevent serious complications.

Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Most patients experienced significant but reversible hair loss during treatment.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

More effective methods are needed to prevent hair loss from chemotherapy.

Adalimumab improved folliculitis decalvans in most patients.

Tofacitinib may help treat hair loss in children with alopecia areata.

The combination therapy was effective and well-tolerated, especially in young patients.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Doxorubicin can block blood vessels from hair follicles, reducing skin tumor growth.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Pemphigus vulgaris involves specific immune cells and B cells that produce antibodies causing skin blisters.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Upadacitinib may cause hair loss.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.